Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review
Health Science Reports · 2026-03 · 9 (3)
DOI: 10.1002/hsr2.72004 ↗At a glance
Übersichtsarbeit in Health Science Reports, published online on 2026-03-04. Written by Zeel Vishnubhai Patel and 8 co-authors. Institution: Internal Medicine Medical College Baroda Gujarat India. 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Hereditary transthyretin‐mediated amyloidosis (hATTR) is a disorder that affects several body systems and can result in life‐threatening conditions like cardiomyopathy and polyneuropathy. For treatment of hATTR in the new medical realm, there is a breakthrough discovery of a medicine called Eplontersen, which targets the underlying genetic mutation causing the condition. This review aims to summarize Eplontersen's mechanism of action, efficacy, safety profile, and ongoing clinical trials.
Methods
A systematic review of the literature was conducted following PRISMA guidelines. Databases searched included PubMed, Cochrane, and Science Direct using terms related to Eplontersen and hereditary amyloidosis. Studies were selected based on defined inclusion and exclusion criteria.
Results
Eplontersen was approved by the FDA after the NEURO‐TTRansform phase 3 trial showed substantial safety and efficacy. The drug demonstrated a significant reduction in serum TTR levels and improvements in neurological function and quality of life in patients with hATTR. The review also explored contraindications, dosing, safety monitoring, and patient support programs.
Conclusion
Although data gaps remain, Eplontersen represents a promising advancement in the treatment of hATTR‐induced polyneuropathy. Future research is needed on long‐term safety, early diagnosis, personalized treatments, and combination therapies. This drug emphasizes the importance of continued research for optimal patient care and outcomes.
Subjects
Author keywords
Authors and institutions
- Internal Medicine Medical College Baroda Gujarat India.
- Liaquat National Hospital and Medical College Karachi Pakistan.
- Internal Medicine Government Medical College Patiala Punjab India.
- Andhra Medical College Visakhapatnam Andhra Pradesh India.
- Internal Medicine Bharati Vidyapeeth University Medical College Pune Maharashtra India.
- Internal Medicine China Medical University Shenyang China.
ORCID profiles: Bethineedi Lakshmi Deepak, Priyadarshi Prajjwal, Serene Sara John, Omniat Amir Hussin
Cite
APA
Patel, Z. V., Kumari, V., Paras, Deepak, B. L., Prajjwal, P., Deep, K. N., Bai, R., John, S. S., & Hussin, O. A. (2026). Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review. Health Science Reports, 9(3). https://doi.org/10.1002/hsr2.72004
Vancouver
Patel ZV, Kumari V, Paras, Deepak BL, Prajjwal P, Deep KN, et al. Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review. Health Science Reports. 2026;9(3). doi:10.1002/hsr2.72004
BibTeX
@article{Patel2026,
author = {Patel, Zeel Vishnubhai and Kumari, Verkha and Paras and Deepak, Bethineedi Lakshmi and Prajjwal, Priyadarshi and Deep, Kolanu Nikhil and Bai, Rakhi and John, Serene Sara and Hussin, Omniat Amir},
title = {Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {3},
doi = {10.1002/hsr2.72004}
}
EUVIMED